Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial.
The aim of our study was to evaluate the efficacy and safety of two concentrations of botulinum toxin A (BTX-A) for the treatment of hemifacial spasm. We randomly divided 20 patients with hemifacial spasm into high- and low-concentration groups; they were administered 50 and 25 U/mL BTX-A injection, respectively. Further, we compared the curative effects and the occurrence of adverse reactions in the two groups. Our results showed that both the concentrations of BTX-A were effective and no significant difference was observed in the onset time and therapeutic efficacy between the two groups; however, the duration of efficacy was longer in the high-concentration group than in the low-concentration group. Patients in both groups had no allergic reactions and systemic toxic reactions, but those in the high-concentration group had more serious adverse reactions and they lasted for longer durations. The adverse reactions in the two groups were not specifically treated, and they resolved in a relatively short time. In conclusion, local injection of BTX-A was effective in treating hemifacial spasm and each concentration of BTX-A had advantages and disadvantages, which indicated that the concentration of BTX-A can be selected according to the clinical characteristics and willingness of the patients.
Department of Neurology, the First People's Hospital of Zhaoqing, Zhaoqing, Guangdong Province, China youjialicn@163.com.
Y J
YJ
Li
Department of Neurology, the First People's Hospital of Zhaoqing, Zhaoqing, Guangdong Province, China.
Y
Y
Huang
Department of Neurology, the First People's Hospital of Zhaoqing, Zhaoqing, Guangdong Province, China.
Q
Q
Ding
Department of Neurology, the First People's Hospital of Zhaoqing, Zhaoqing, Guangdong Province, China.
Z H
ZH
Gu
Department of Neurology, the First People's Hospital of Zhaoqing, Zhaoqing, Guangdong Province, China.
X L
XL
Pan
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D064420:Drug-Related Side Effects and Adverse Reactions / Q000473:pathology; D005260:Female; D019569:Hemifacial Spasm / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged
D019274:Botulinum Toxins, Type A